AgeX Therapeutics, Inc.
About AgeX Therapeutics, Inc.
The mission of AgeX is to apply technology related to pluripotent stem cells and telomere biology to aging and age-related disease. AgeX is expected to have three initial areas of focus: 1) the development of pluripotent stem cell-derived brown adipocytes for the treatment of Type II diabetes and potentially obesity; 2) the development of vascular progenitors to improve circulation to ischemic tissues in patients suffering from heart disease; and 3) Induced Tissue Regeneration (iTR)TM - an emerging technology invented and patented by BioTime scientists that is designed to profoundly reprogram aged tissues in the body in a way that can restore a regenerative phenotype normally expressed only in the first few weeks of human development.83 articles with AgeX Therapeutics, Inc.
-
Dr. Joanne Hackett Appointed Chairperson of AgeX Board of Directors
5/18/2022
AgeX Therapeutics, Inc., a biotechnology company developing therapeutics for human aging and regeneration, announced that Dr. Joanne Hackett has been appointed Chairperson of AgeX’s Board of Directors.
-
AgeX Therapeutics Reports First Quarter 2022 Financial Results
5/13/2022
AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended March 31, 2022.
-
AgeX Therapeutics Reports Fourth Quarter and Annual 2021 Financial Results
3/29/2022
AgeX Therapeutics, Inc., a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended December 31, 2021.
-
AgeX Therapeutics to Collaborate With University of California, Irvine, on Research Program for Exosome-Based Therapies for Certain Brain Disorders
12/14/2021
AgeX Therapeutics , Inc. announced today a research collaboration with the University of California, Irvine (UCI).
-
AgeX Therapeutics’ Licensee ImStem Biotechnology Announces First U.S. Multiple Sclerosis Patient Dosed with IMS001
11/30/2021
AgeX Therapeutics, Inc. announced today that ImStem Biotechnology, Inc. (“ImStem”), a biopharmaceutical company developing human embryonic stem cell (ESC)-derived mesenchymal stem cells, has dosed the first U.S. multiple sclerosis (MS) patient with ImStem’s lead investigational drug candidate IMS001 at the Shepherd Center in Atlanta, GA.
-
AgeX Therapeutics Reports Third Quarter 2021 Financial Results
11/12/2021
AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended September 30, 2021.
-
AgeX Therapeutics Reports Second Quarter 2021 Financial Results
8/13/2021
AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended June 30, 2021.
-
AgeX Therapeutics and LyGenesis Terminate Merger Negotiations
7/23/2021
AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and cell regeneration, and LyGenesis, Inc. (“LyGenesis”), a privately held biotechnology company developing cell therapies that enable organ regeneration, announced today that they have discontinued negotiations for a merger agreement.
-
AgeX Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
5/17/2021
AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended March 31, 2021.
-
AgeX Therapeutics Reports Fourth Quarter and Annual 2020 Financial Results and Provides Business Update
3/31/2021
AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the fourth quarter and the full year ended December 31, 2020.
-
AgeX Announces Preprint Article Relating to Regeneration, Aging, and Cancer
3/12/2021
AgeX Announces Preprint Article Relating to Regeneration, Aging, and Cancer
-
AgeX Therapeutics to Collaborate with The Ohio State University to Generate Proof-of-Concept Animal Data for AgeX’s Brown Adipose Tissue (BAT) Cell Therapy Candidate for Diabetes and Obesity
3/10/2021
Research to utilize AgeX’s proprietary BAT cellular product candidate AgeX-BAT1. Loss of non-shivering thermogenic BAT, also known as brown or good fat, in humans with aging is associated with obesity, type II diabetes, and cardiovascular disease. Studies to evaluate if transplantation of AgeX-BAT1 in mice improves diet-induced obesity, metabolic health including glucose metabolism, and cardiac function.
-
AgeX Therapeutics and LyGenesis to Negotiate Merger Agreement
3/2/2021
AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and cell regeneration, and LyGenesis, Inc. (“LyGenesis”), a privately held biotechnology company developing cell therapies that enable organ regeneration, announced today that they will proceed to negotiate an agreement
-
AgeX Therapeutics, Inc. Announces That Its Annual Meeting of Stockholders Will Be Conducted Online Only
12/22/2020
AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE) announced today that due to state and county government health orders, attendance at the AgeX 2020 Annual Meeting of Stockholders (the “Annual Meeting”) to be held at 10:00 a.m. Pacific Standard Time on Monday, December 28, 2020 will be permitted only through online participation
-
AgeX Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
11/16/2020
Sublicensed stem cell line ESI-053 to ImStem Biotechnology for development of cell therapy candidate IMS001 for COVID-19 and acute respiratory distress syndrome from other causes. Expanded agreement related to ESI clinical-grade pluripotent stem cell lines to provide AgeX independence to sublicense ESI lines to industry and academia for development of cellular therapeutics.
-
AgeX Therapeutics Sublicenses Stem Cell Line ESI-053 to ImStem Biotechnology for Development of Cell Therapy Candidate IMS001 for COVID-19 and Acute Respiratory Distress Syndrome
10/28/2020
Emerging Preclinical and Clinical Data Support Potential of Mesenchymal Stem Cells (MSCs) to be Useful in COVID-19 and Acute Respiratory Distress Syndrome (ARDS) from Other Causes ImStem’s MSC Product Candidate IMS001 is Derived from AgeX’s Stem Cell Line ESI-053 IMS001, which Recently Gained FDA IND Clearance to Begin Human Study in Multiple Sclerosis, to be Considered for Development in COVID-19 and ARDS More Generally
-
AgeX Therapeutics and Lineage Cell Therapeutics Announce Expansion of Agreement Related to ESI Clinical-grade Pluripotent Stem Cell Lines for Therapeutic Purposes
9/9/2020
AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a company focused on developing and commercializing innovative therapeutics for human aging, and Lineage Cell Th
-
AgeX Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update
8/14/2020
AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported financial and operating results for the second quarter ended June 30, 2020. AgeX made strides with respect to its newly established licensing and collaboration model, which aims to embed its technology platforms across the cell therapy industry. AgeX has entered into a rese
-
AgeX Therapeutics and Pluristyx Announce Manufacturing, Marketing, and Distribution Agreement to Expand Access to Clinical-Grade Human Pluripotent Stem Cells for Therapeutic Applications
6/16/2020
Allows industry and academia access to cGMP-grade, NIH-registered AgeX ESI human pluripotent stem cells for development of cellular therapeutics AgeX ESI cell lines are among only a few pluripotent stem cell lines from which derived cell therapy candidates have been granted FDA IND clearance to begin human trials Pluristyx will manufacture, market, and distribute Ready-to-Use™ and Ready-to-Differentiate™ ESI stem cell lines vialed and frozen o
-
AgeX Therapeutics Receives Stock Exchange Deficiency Letter
6/5/2020
AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on June 1, 2020 AgeX received a Deficiency Letter from the staff of the NYSE American (the “Exchange”) indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Section 1003(a)(i) of the Exchange Company Guide in that Age